RETRACTED: Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma

Kabel, Ahmed M.; Atef, Aliaa; Estfanous, Remon S.

doi:10.1016/j.biopha.2017.10.149

Cited by 35 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They act by increasing certain hormones that stimulate the pancreas to produce more insulin and inhibit hepatic gluconeogenesis [9]. Sitagliptin was reported to possess pleiotropic antioxidant and antiinflammatory properties which may have beneficial effects on various body tissues [10].…”

mentioning

confidence: 99%

“…Also, calcipotriol in the present study was able to restore the activities of the antioxidant enzymes and decrease the level of TBARS. Vitamin D analogues, including calcipotriol, have strong antioxidant properties which may be attributed to decreased production of reactive oxygen species and restoration of the protective mechanisms that protect the body against oxidative stress [12].Neuroinflammation was considered as the cornerstone in the pathophysiology of AD[26].NF-κB is a protein complex that controls DNA transcription, production of the proinflammatory cytokines and cell survival[10]. Freudlsperger et al[27] reported that the cross-talk that exists between NF-κB and TGF-β1 signaling pathways is the triggering event that induces the production of the proinflammatory cytokines such as TNF-α and IL-6 which may have potential effects on memory and cognition.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ameliorative potential of sitagliptin and/or calcipotriol on lipopolysaccharide-induced Alzheimer's disease

Kabel

Borg

Elmaaboud

et al. 2019

BESPS

View full text Add to dashboard Cite

Background: Alzheimer's disease (AD) is a progressive neuropsychiatric disorder that causes dementia. It mostly affects people older than 65 years. The exact mechanisms of AD are not fully understood but affection of apoptosis, oxidative stress and neuroinflammation may be contributing factors. Aim: To evaluate the ability of sitagliptin and/or calcipotriol to attenuate lipopolysaccharide (LPS)-induced AD in mice and to elucidate their possible mechanisms of action. Methods: Sixty male Balb/c mice were divided into 6 equal groups: Control; LPS; LPS + carboxymethyl cellulose; LPS + Sitagliptin; LPS + Calcipotriol; and LPS + Sitagliptin + Calcipotriol group. Behavioral tests, tissue catalase (CAT), superoxide dismutase (SOD) and thiobarbituric acid derivatives (TBARS) were assessed. Also, tissue transforming growth factor beta-1 (TGF-β1), tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) were determined. Parts of the hippocampus were subjected to histopathological, immunohistochemical and electron microscopic examination. Results: Administration of sitagliptin and/or calcipotriol prior to LPS injection induced significant increase in the recognition index, tissue CAT and SOD associated with significant decrease in tissue TBARS, TNF-α, IL-6 and TGF-β1 and significant improvement of the histopathological, immunohistochemical and electron microscopic picture compared to LPS group. These changes were significant in sitagliptin/calcipotriol combination group compared to the use of each of these drugs alone. Conclusion: Sitagliptin/calcipotriol combination might represent a new therapeutic modality for amelioration of Alzheimer's disease.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Ameliorative potential of sitagliptin and/or calcipotriol on lipopolysaccharide-induced Alzheimer's disease

Kabel

Borg

Elmaaboud

et al. 2019

BESPS

View full text Add to dashboard Cite

show abstract

“…[ 49 ] In agreement with our results, another study showed a decreased LDH level by the treatment of sitagliptin and/or resveratrol on experimentally induced clear cell renal carcinoma. [ 50 ] Post‐treatment of resveratrol and nicotinamide increased the level of LDH, suggesting the action of nicotinamide as resveratrol antagonist.…”

Section: Discussionmentioning

confidence: 99%

SIRT1‐mediated amelioration of oxidative stress in kidney of alcohol‐aflatoxin‐B1‐induced hepatocellular carcinoma by resveratrol is catalase dependent and GPx independent

Rawat

Shrivastava

Naik

et al. 2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a type of primary liver cancer and dietary exposure to aflatoxins is a major risk factor of HCC. The current study aimed to assess the role of resveratrol and nicotinamide in renal toxicity during alcohol‐aflatoxin‐B1‐induced HCC. The results revealed that resveratrol treatment normalized the level of urea, lipid peroxidation, lactate and lactate dehydrogenase, which were increased in HCC. It also downregulated the increased expression of sirtuin 1 in HCC kidney. Furthermore, amelioration of oxidative stress in kidney of HCC rats by resveratrol was observed to be catalase dependent and glutathione peroxidase independent.

show abstract

“…Sitagliptin is a widely used oral hypoglycemic agent. Moreover, studies have reported that sitagliptin inhibits the development of various tumors both in vitro and in vivo 5,6 . Till now, research regarding the inhibition of cancers by sitagliptin has primarily focused on the analysis of clinical data, and knowledge of its molecular mechanism remains limited.…”

Section: Discussionmentioning

confidence: 99%

“…Sitagliptin, as a dipeptidyl peptidase‐IV (DPP4) inhibitor, could reduce glucagon levels and increase insulin levels by promoting the secretion of intestinal hormones 3 . Previous researches have shown that sitagliptin can reduce the risk of multiple tumors including breast, 4 kidney, 5 and colon cancer, 6 as well as improve the prognosis. However, there are few reports on the effects of sitagliptin on GC.…”

Section: Introductionmentioning

confidence: 99%

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Wang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes-associated protein (YAP) promotes the proliferation and poor prognosis of multiple tumors. However, the ability of sitagliptin to regulate YAP and its effects on gastric cancer (GC) cells remain unclear. Here, we first showed that sitagliptin inhibited the proliferation of GC cells, and this inhibition was regulated by Hippo pathway. Sitagliptin phosphorylated YAP in a large tumor suppressor homolog-dependent manner, thereby inhibiting YAP nuclear translocation, and promoted YAP cytoplasm retention. This inhibition can be blocked by adenosine 5′-monophosphate-activated protein kinase (AMPK). Moreover, sitagliptin could reduce the expression of tumor-testis antigen Melanoma-associated antigen-A3 through YAP. In conclusion, sitagliptin may have a potential inhibitory effect on GC by AMPK/YAP/ melanoma-associated antigen-A3 pathway. K E Y W O R D Sgastric cancer, MAGE-A3, sitagliptin, YAP

show abstract

RETRACTED: Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma

Cited by 35 publications

References 51 publications

Ameliorative potential of sitagliptin and/or calcipotriol on lipopolysaccharide-induced Alzheimer's disease

Ameliorative potential of sitagliptin and/or calcipotriol on lipopolysaccharide-induced Alzheimer's disease

SIRT1‐mediated amelioration of oxidative stress in kidney of alcohol‐aflatoxin‐B1‐induced hepatocellular carcinoma by resveratrol is catalase dependent and GPx independent

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Contact Info

Product

Resources

About